ATE71225T1 - Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten. - Google Patents

Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.

Info

Publication number
ATE71225T1
ATE71225T1 AT85850256T AT85850256T ATE71225T1 AT E71225 T1 ATE71225 T1 AT E71225T1 AT 85850256 T AT85850256 T AT 85850256T AT 85850256 T AT85850256 T AT 85850256T AT E71225 T1 ATE71225 T1 AT E71225T1
Authority
AT
Austria
Prior art keywords
sialosyllactotetraose
associated antigen
diagnosis
specific tumor
cancer diseases
Prior art date
Application number
AT85850256T
Other languages
English (en)
Inventor
Jan Roland Holmgren
Leif Gustav Lindholm
Lars Torvald Svennerholm
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Application granted granted Critical
Publication of ATE71225T1 publication Critical patent/ATE71225T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT85850256T 1984-08-28 1985-08-06 Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten. ATE71225T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8404283A SE455445B (sv) 1984-08-28 1984-08-28 Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik
EP85850256A EP0173663B1 (de) 1984-08-28 1985-08-06 Verwendung eines spezifischen tumorassoziierten Antigens, Sialosyllactotetraose, in Diagnose- oder Therapieverfahren bezüglich Krebskrankheiten

Publications (1)

Publication Number Publication Date
ATE71225T1 true ATE71225T1 (de) 1992-01-15

Family

ID=20356831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85850256T ATE71225T1 (de) 1984-08-28 1985-08-06 Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.

Country Status (5)

Country Link
EP (1) EP0173663B1 (de)
JP (1) JPH0690204B2 (de)
AT (1) ATE71225T1 (de)
DE (1) DE3585061D1 (de)
SE (1) SE455445B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287916A1 (de) * 1987-04-13 1988-10-26 Otsuka Pharmaceutical Co., Ltd. Immunoassay
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0380084A3 (de) * 1989-01-27 1991-03-13 The Biomembrane Institute Methode zur Hemmung dvon Zell-Zell- und Zellsubstrat-Wechselwirkungen durch Blockierung der Kohlenhydrat-Kohlenhydrat-Wechselwirkungen
WO1990010708A1 (en) * 1989-03-09 1990-09-20 The Sendai Institute Of Microbiology Monoclonal antibody, and assay method, reagent kit, search method and drug missile using said antibody
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
PL2087002T3 (pl) 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4569788A (en) * 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer

Also Published As

Publication number Publication date
SE8404283L (sv) 1986-03-01
EP0173663A2 (de) 1986-03-05
SE8404283D0 (sv) 1984-08-28
DE3585061D1 (de) 1992-02-13
EP0173663B1 (de) 1992-01-02
JPS61116660A (ja) 1986-06-04
JPH0690204B2 (ja) 1994-11-14
SE455445B (sv) 1988-07-11
EP0173663A3 (en) 1987-10-07

Similar Documents

Publication Publication Date Title
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
IT8419266A1 (it) Dispositivo per generare calore in tessuti" del corpo umano e procedimento di cenerazione di calore, particolarmente per la cura di tumori
DK2289D0 (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
ATE486938T1 (de) C-typ-lektin-transmembran-antigen, das in menschlichem prostatakrebs exprimiert wird, und verwendungen dieses antigens
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
ATE216266T1 (de) Einen liganden enthaltendes arzneimittel zur behandlung und/oder diagnose von weichgeweben- tumoren
DK402485A (da) Tumorterapeutiskum og fremgangsmaade til dets fremstilling
ES2012997A6 (es) Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.
DE3582191D1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
ZA884777B (en) Antigen recognized by mca 16 88
EP0232706A3 (de) Blutgruppe-Antigen-Platte
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
NO883040L (no) Middel for undersoekelse av tumorer, samt fremgangsmaate for fremstilling av et slikt middel.
EP0584267A4 (de) Tumorspezifischer monoklonaler antikörper 81av78.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time